Although multiple studies favoured the use of intranasal insulin in humans after showing better cognitive function with few adverse effects, no formulation has gained regulatory approval for AD treatment due to a lack of clinical success and safety issues [4, 9, 56]. The gene discussed is INS; the disease is Alzheimer disease.